May 24, 2023 03:06 PM EDT

District court hands Janssen a win in patent feud with Viatris

Paul Schloesser

Associate Editor

Johnson & Johnson’s Janssen has a new court win related to its antipsychotic drug.

A judge on Monday ruled that Mylan’s proposed labels for a generic version of paliperidone, Janssen’s antipsychotic drug, would infringe on one of Janssen’s patents, per an opinion and order filed in New Jersey District Court. (Mylan merged with Pfizer’s Upjohn unit in a deal that closed in late 2020 and is now called Viatris.)

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

District court hands Janssen a win in patent feud with Viatris

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

FDA adcomm votes unanimously in favor of full approval for Eisai's new Alzheimer's drug

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Second round of inflation-related rebates hits 43 drugs from Amgen, Seagen, AbbVie and others

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Dis­trict court hands Janssen a win in patent feud with Vi­a­tris

Paul Schloesser

Associate Editor

To read Endpoints News become a free subscriber

FDA ad­comm votes unan­i­mous­ly in fa­vor of full ap­proval for Ei­sai's new Alzheimer's drug

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Sec­ond round of in­fla­tion-re­lat­ed re­bates hits 43 drugs from Am­gen, Seagen, Ab­b­Vie and oth­ers

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

District court hands Janssen a win in patent feud with Viatris

FDA adcomm votes unanimously in favor of full approval for Eisai's new Alzheimer's drug

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Second round of inflation-related rebates hits 43 drugs from Amgen, Seagen, AbbVie and others

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape